Home
Istituto Gentili

Istituto Gentili Market Share Analysis for August 2026

Istituto Gentili is an Italian biopharmaceutical company with over a century of history in the field of oncology and oncohematology. Discover more.

Industry: N/A

Domainistitutogentili.com

Year Founded1917

Employees51 - 200

Annual Revenue--

Istituto Gentili

Istituto Gentili (including company regionals)

istitutogentili.com

See more website traffic and engagement information

Total visits to Istituto Gentili's top domains

Understand Istituto Gentili market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

istitutogentili.com5K

See more with Sales Intelligence

Avg. visit duration in Istituto Gentili's top domains

Analyze Istituto Gentili engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

istitutogentili.com00:00:20

See more with Sales Intelligence

Avg. pageviews on Istituto Gentili's top domains

See how Istituto Gentili keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

istitutogentili.com1.95

See more with Sales Intelligence

Istituto Gentili top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Istituto Gentili

These are the website technologies, by industry, used by Istituto Gentili top domains

Advertising (2)

PubMatic

Business Solutions (1)

DocuSign

Content Management System (1)

Umbraco

Conversion & Analytics (1)

Google Custom Search Engine

More Technologies

6

See all

News & Signals from Istituto Gentili

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPOA Pharma GmbH partners with Istituto Gentili S.r.l..POA Pharma Scandinavia strengthens Nordic portfolio through partnership with Istituto Gentili.

NewsGalen Ltd partners with Istituto Gentili S.r.l..Northern Ireland based Galen has announced a new licensing partnership with Istituto Gentili, under which Galen's subsidiary, POA Pharma Scandinavia, will become the sole distributor of Ozalin (2mg/ml oral midazolam solution) across the Nordic region, including Denmark, Finland and Norway.